Guerbet's Vectorio Receives Registration in Taiwan

By News Release


Guerbet (GBT), a global specialist in medical imaging, announces that the Ministry of Health & Welfare delivered registration for its innovative system for interventional oncology, Vectorio®, in Taiwan.

Vectorio® is a set of Lipiodol® Ultra Fluid resistant medical devices (1) including patented syringes, stopcock and sampling devices.

Vectorio® is dedicated for mixing and delivering Lipiodol® Ultra Fluid & anticancer drugs during cTACE procedure in adults with known, intermediate-stage hepatocellular carcinoma (HCC).

HCC is the most common primary liver cancer and is the fourth biggest cause of death due to cancer worldwide (2).

This medical device offers multiple advantages for healthcare professionals:

  • 24 hours Lipiodol® Ultra Fluid resistance (1) - Reduce risks of leakage.
  • Patented 3-way stopcock with 4 connections offering possibility of "On-table mixing" (interventional radiologists have the possibility of remixing without disconnection from the micro-catheter, thus maximizing the safety during the intervention).
  • Ready-to-use set: all devices in one set.
  • User-friendly: Ergonomic and quick device set-up, improving cTACE procedures for physicians.

Designed and manufactured in France, Vectorio® 's commercial launch started in September 2017 in European countries. Today, Vectorio® is registered in 25 countries over the world: two countries where Vectorio® is registered for HCC imaging procedures, Canada & Germany; and 23 countries where Vectorio® is registered for cTACE procedures (3).


  1. Test report (E17-41) - Verification report of the device's functionality after 24h exposure to Lipiodol.
  2. WHO - Globocan 2018 (IARC) Global Cancer Observatory.
  3. Countries in which Vectorio®is registered for cTACE: EMEA (Austria, Belgium, Czech Republic, Denmark, France, Hungary, Ireland, Luxembourg, Portugal, Switzerland, The Netherlands, Turkey), Americas (Argentina, Brazil, Mexico, Peru), Asia-Pacific (Hong Kong, India, New Zealand, South Korea, Taiwan, Thailand, Vietnam). Vectorio® is also registered for HCC imaging in Germany & Canada.
  4. Countries in which cTACE indication is registered for Lipiodol®Ultra Fluid: EMEA (Austria, Belgium, Czech Republic, Denmark, France, Hungary, Iran, Ireland, Luxembourg, Portugal, Switzerland, The Netherlands, Tunisia, Turkey), Americas (Argentina, Colombia, Brazil, Chile, Mexico, Peru), Asia-Pacific (Brunei Darussalam, Cambodia, Hong Kong, India, Mongolia, New Zealand, Philippines, South Korea, Sri Lanka, Taiwan, Thailand, Vietnam). Countries in which HCC imaging indication is registered for Lipiodol® Ultra Fluid: Canada, Germany, United States of America.
  5. De Baere T. et al., Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion, Cardiovasc Intervent Radiol,2016;39: 334-343.
Back To Top

Guerbet's Vectorio Receives Registration in Taiwan.  Appl Rad Oncol. 

By News Release| February 06, 2020
Categories:  Section|Technologies

About the Author

News Release

News Release

Copyright © Anderson Publishing, Ltd

    Agility CMS